GSK goes East again, snagging option on preclinical DualityBio ADC for $30M

GSK has made another trip to China to build out its antibody-drug conjugate (ADC) pipeline, returning with an option on a preclinical Duality Biologics candidate that could ultimately cost the Big Pharma $1 billion.